Complex pathways to ceftolozane-tazobactam resistance in clinical *Pseudomonas aeruginosa* isolates: a genomic epidemiology study

Hoai-An Nguyen[1], Anton Y. Peleg[1,2,3], Jiangning Song[3,4], Jessica A. Wisniewski[1†], Luke V. Blakeway[1†], Gnei Z. Badoordeen[1†], Ravali Theegala[1†], Nhu Quynh Doan[1], Matthew H. Parker[1], David L. Dowe[5] and Nenad Macesic*[1,3]

[1]Department of Infectious Diseases, The Alfred Hospital and School of Translational Medicine, Monash University, Melbourne, Australia.

[2]Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Melbourne, Australia.

[3]Centre to Impact AMR, Monash University, Melbourne, Australia

[4]Monash Biomedicine Discovery Institute, Department of Biochemistry & Molecular Biology, Monash University, Melbourne, Australia

[5]Department of Data Science & AI, Monash University, Melbourne, Australia.

* Corresponding Author

Nenad Macesic, Department of Infectious Diseases, The Alfred Hospital and School of Translational Medicine, Monash University, Level 1, The Alfred Lane House, 11 Alfred Ln, Melbourne, VIC 3004, Australia.

nenad.macesic1@monash.edu

†No longer at the institution where the work was performed.

Keywords:

Ceftolozane/tazobactam, antimicrobial resistance, *Pseudomonas aeruginosa*, genome-wide

association studies, machine learning.

Abstract

Objectives

We aimed to conduct a comprehensive genomic analysis of ceftolozane/tazobactam (C/T)

resistance mechanisms in *Pseudomonas aeruginosa* by combining novel institutional data

with publicly available sequencing data.

Methods

We analyzed 1,682 *P. aeruginosa* isolates, comprising 339 isolates from Alfred Hospital

(Melbourne, Australia) and 1,343 isolates from six public datasets. All isolates underwent

whole-genome sequencing and C/T broth microdilution (BMD) susceptibility testing. We

assessed previously reported intrinsic and acquired resistance mechanisms. We then

conducted a genome-wide association study (GWAS) and machine learning analysis to

identify novel genes associated with resistance. We then evaluated the impact of mutations in

these genes on MIC values and ceftolozane binding affinity.

Results

Among 1,682 *P. aeruginosa* isolates representing 527 distinct sequence types, 343 (20.4%)

were C/T-resistant. Carbapenemase genes were detected in 206/1,682 (12.2%) isolates.

Mutations in previously reported resistance-associated genes (*ftsI, mpl, ampD, ampC, ampR,

oprD)* were more frequent in resistant isolates but were also found in almost all susceptible

isolates. Successive mutations conferred additive increases in MIC. Combined GWAS and

machine learning analyses *a priori* identified five key genes significantly associated with

resistance: *ftsI*, *ampR*, *ampC*, PA3329, and PA4311. Molecular docking simulation revealed

that the R504C mutation in penicillin-binding protein 3 (PBP3), which is encoded by *ftsI*,

reduced binding contacts and hydrogen bonds with ceftolozane, significantly decreasing

binding affinity (P=0.016).

Conclusions

Our analysis of 1,682 *P. aeruginosa* genomes demonstrated complex pathways to C/T

resistance and showed that *ftsI* may play an underappreciated role. We discovered two

previously unidentified genes associated with C/T resistance, whose function remains to be

determined.

Introduction

Pseudomonas aeruginosa is a key Gram-negative pathogen, accounting for 9.4% of global antimicrobial resistance (AMR)-attributable deaths in 2021[1]. Multidrug-resistant (MDR) *P. aeruginosa* forms 15-30% of total *P. aeruginosa* infections[2], severely limiting available treatment options. Consequently, ceftolozane-tazobactam (C/T) has emerged as a first-line treatment for MDR *P. aeruginosa* infections[3]. However, rates of C/T resistance in MDR *P. aeruginosa* can be as high as 18.4%[4]. This highlights the urgent need to understand C/T resistance mechanisms, in order to rapidly identify resistant isolates and better control their spread.

There are multiple pathways contributing to C/T resistance[5]. Of these, structural alterations in AmpC β-lactamase represent most common mechanism[6-8]. AmpC hyperproduction, resulting from mutations in regulatory genes (*ampD*, *ampR*, and *dacB*), also confers resistance[6,7]. Acquired AMR genes such as carbapenemases or extended-spectrum β-lactamases represent another major mechanism due to their ability to hydrolyze ceftolozane[8,9]. Other mechanisms include mutations in *ftsI*, encoding penicillin-binding protein 3 (PBP3), and DNA polymerase subunits gama and tau[7,10].

Previous studies on C/T resistance have largely focused on case series and well-described mechanisms[7,8,11]. However, the complex interplay between different resistance mechanisms remains poorly understood, and the identification of novel resistance determinants has been limited. To address these gaps, we aimed to comprehensively determine C/T resistance mechanisms using novel data from our institution combined with all publicly-available *P. aeruginosa* genomes with matched C/T susceptibility phenotypes. Specifically, we aimed to

assess prevalence of known resistance mechanisms, then identify novel mechanisms through

a genome-wide association study (GWAS) and machine learning (ML) approaches (**Figure 1**).

Materials and methods

Bacterial isolates collection

The study was reviewed and approved by the Alfred Hospital Ethics Committee (Project No.

185/21). We analysed *P. aeruginosa* isolates collected between 2004-2021 at the Alfred

Hospital (Melbourne, Australia), a 638-bed quaternary hospital with a cystic fibrosis and lung

transplant state referral service. All isolates underwent short-read sequencing (Illumina). We

identified six public datasets containing both whole-genome sequencing (WGS) data and

antimicrobial susceptibility testing (AST) results[5,10,12-15]. To ensure standardized resistance

determination, we included only datasets where minimum inhibitory concentrations (MIC) were

determined using broth microdilution (BMD), the reference method. The in-house sequence

files have been deposited in NCBI project ID PRJNA1220180.

Antimicrobial susceptibility testing

For our in-house isolates, we conducted BMD using the ThermoFisher Sensititre plate (code:

DKMGN) to determine C/T MIC values. We used the European Committee on Antimicrobial

Susceptibility Testing (EUCAST) v15.0 breakpoints (MIC $\leq$ 4mg/L) to classify isolates as

'susceptible' or 'resistant'[16].

WGS data processing

De novo short-read assembly was generated using Unicycler v0.5.0[17]. Species confirmation

and multi-locus sequence typing (MLST) were conducted via Pathogenwatch

(https://pathogen.watch). Acquired AMR genes were detected using AMRFinderPlus

v3.11.18[18]. For chromosomal mutations analysis, we assessed mutations in ten genes

previously linked to C/T resistance, as described by Cortes-Lara et al.[5]. Additionally, we

included *oprD* due to its involvement in resistance following C/T exposure (see Supplementary

Methods)[7].

Identifying variants associated with C/T resistance

We conducted GWAS on susceptible/resistant phenotypes using a mixed-effects model

implemented in pyseer v1.3.10[19]. Unitigs were used as testing variants, with a phylogeny-

based pairwise distance matrix incorporated to control for population structure. Association

mapping was performed using the annotated PAO1 reference genome (Genbank:

GCA_000006765.1). To reduce false positives and computational load, we applied a two-step

filtering strategy: first identifying GWAS-significant variants, then retaining only those that also

contributed to ML-based C/T resistance prediction (See Supplementary Methods).

Binding affinity analysis

We assessed the binding affinity between ceftolozane and proteins encoded by GWAS-

significant genes, comparing both wild-type and mutant variants. 3D structures of proteins

were predicted using ColabFold, an AlphaFold-based tool[20]. Molecular docking simulations

were performed using AutoDock Vina v1.2.5[21], and results were visualised using PyMOL[22].

Results

Data characteristics

We analysed 1,682 *P. aeruginosa* isolates from four continents (Asia, Europe, North America,

Oceania) (**Supplementary File 1**), including Alfred Hospital isolates (339/1,682, 20.2%) and

six public datasets (1,343/1,682, 79.8%)[5,10,12-15]. C/T resistance was noted in 343/1,682

(20.4%) isolates. We detected 527 sequence types (STs) (**Supplementary Figure 1**). *P.*

aeruginosa ST235, a well-recognised global MDR lineage was most frequent (163/1,682,

9.7%) and accounted for 78/343 (22.8%) of C/T resistant isolates. Resistance rates in

common ST groups can be found in **Supplementary Table 1**.

Prevalence of acquired AMR genes

We first analysed acquired C/T resistance determinants. Carbapenemase genes were noted

in 206/1,682 (12.2%) isolates (**Supplementary Table 2**), including serine carbapenemase

(bla_{GES}, bla_{KPC}) and metallo-β-lactamase genes (bla_{IMP}, bla_{VIM}, bla_{NDM}). Carbapenemase

acquisition strongly predicted C/T resistance, with 202/206 (98.1%) carbapenemase-positive

isolates being C/T resistant. Only bla_{GES-5} was found in C/T-susceptible isolates (4/206, 1.9%).

The most common carbapenemase was bla_{NDM-1} (37/206, 18.0%), followed by bla_{IMP-4}

(31/206, 15.0%), bla_{IMP-1} (29/206, 14.1%), bla_{VIM-2} (25/206, 12.1%) and bla_{GES-5} (22/206,

10.7%). Dual carbapenemases were identified in six isolates. Analysis of OXA-type β-

lactamases revealed 52 distinct genes (**Supplementary Figure 3**). Of these, bla_{OXA-10}, bla_{OXA-14},

$_{14}$, $bla_{OXA-141}$, $bla_{OXA-210}$, $bla_{OXA-796}$ and $bla_{OXA-846}$ were significantly more prevalent in C/T-

resistant isolates, with bla_{OXA-14}, $bla_{OXA-141}$, $bla_{OXA-210}$, and $bla_{OXA-796}$ found exclusively in

resistant isolates. VEB-type β-lactamases were detected only in C/T-resistant isolates (8/343,

2.0%), with 4/8 co-harboring additional carbapenemases: two with bla_{KPC-2}, one with bla_{VIM-5},

and one with bla_{NDM-1}.

Analyses of known chromosomal C/T resistance mechanisms

We then assessed prevalence of mutations in a curated list of eleven intrinsic genes associated with C/T resistance (*ampC* and its regulators, mexAB-oprM overexpression pathway, *ftsI, galU* and *oprD*, **Figure 2A-C, Supplementary Table 3**)[5]. We specifically excluded isolates with acquired resistance determinants that likely conferred C/T resistance alone (carbapenemase genes, VEB-type β-lactamases, OXA-type β-lactamases with significantly higher prevalence in resistant isolates), as the impact of additional mutations would be unclear. This resulted in a subset of 1,442 isolates (including 114 resistant isolates), which we will refer to as the 'intrinsic resistance' dataset. Mutations in genes associated with resistance were noted in all resistant isolates but also in 1,319/1,328 (99.3%) susceptible isolates (**Supplementary Table 3**). For instance, *ampC* mutations were observed in 94.7% of resistant and 84.7% of susceptible isolates.

Given this high prevalence, we further focused on mutations with a previously reported high impact on C/T susceptibility. These were significantly more frequent in resistant than susceptible isolates (in order of significance): *ftsI* (24/114 resistant vs. 22/1,328 susceptible isolates, P=2.70×10^{-28}), *mpl* (12/114 vs. 44/1,328, P=3.53×10^{-4}), *ampD* (9/114 vs 37/1,328, P=0.007), *ampC* (53/114 vs 461/1,328, P=0.016), and *ampR* (12/114 vs 73/1,328, P=0.048). In terms of specific mutations, for *ftsI* the R504C mutation was most prevalent (21/114 [18.4%] resistant vs 17/1328 [1.3%] susceptible isolates). Notably, it was distributed across 18 unique STs in the resistant group. The previously reported F533L and E466K mutations were found in 1/114 (0.9%) and 0 C/T-resistant isolates, respectively[23,24]. For known *ampC* mutations[25], E247G and deletions in the G229-E247 region (△G at L237, △P241-A246, and △R238-

L244) were found in one and three resistant isolates, respectively, and in no susceptible isolates.

Inactivated *oprD* was also more frequent in resistant isolates (77/114 [67.5%] vs 623/1328 [50.5%], P=3.60×10^{-5}). Frameshift due to indels was the most common mutation in both resistant (26/114, 22.8%) and susceptible (249/1328, 18.8%) isolates. For other canonical C/T resistant genes, mutations in the *mexAB-oprM* efflux pump regulators (*nalC*, *nalD*, and *mexR*) were very frequent in the resistant group, occurring in 110/114 (96.5%). Mutations in *galU* were noted in only 3/114 (2.6%) resistant isolates, while no mutations were detected in *dacB*.

Analysis of combinations of mutations in C/T resistance-associated genes revealed 53 distinct mutational pathways in resistant isolates (**Figure 2B**). Multiple mutations were common, with only 1/56 (1.8%) pathways involving a single mutation. Notably, all resistant isolates harbored at least one mutation in either *ampC* or its overexpression regulators (*ampR*, *ampD*, *mpl*). At the AMR mechanism level, collapsing *ampC*-related genes and *mexAB-oprM*-related genes into functional groups revealed seven distinct resistance pathways (Figure 2C). Among these, only modifications in AmpC and its regulatory genes emerged as a standalone pathway capable of conferring C/T resistance.

We next investigated the impact of multiple mutations on MIC, firstly by including both low- and high-impact mutations (**Figure 2D**, **Supplementary Figure 3A**), then high-impact mutations only (**Figure 2E**, **Supplementary Figure 3B**). We observed a monotonic increase in MIC with increasing number of mutations in both analyses. High-impact mutations were associated with higher MIC increases, with a single mutation able to achieve resistant MICs

(mean: 3.98 mg/L, SD: 10.33, **Figure 2E**) per EUCAST breakpoints (4 mg/L). When

considering both low- and high-impact mutations, six or more mutations were required to

achieve the same effect (**Figure 2D)**.

Identifying novel C/T resistance mechanisms through GWAS and ML analysis

Using the 'intrinsic resistance' dataset (n=1,442), we conducted GWAS and identified 290

significant variants out of 2,305,235 unitigs tested (Bonferroni-adjusted P=2.17 × 10^{-8};

Supplementary Figure 4). Mapping to the PAO1 reference genome annotated 260 unitigs

corresponding to 73 genes (**Supplementary Table 4**). Top associated genes included *ftsI*

(P=2.02×10^{-23}), *hsbR* (P=3.33×10^{-20}), *ampR* (P=2.71×10^{-16}), *ampC* (P=4.32×10^{-15}), and

several hypothetical proteins, including PA3329 (P=1.00×10^{-15}), PA4311 (P=5.55×10^{-15}), and

PA2418 (P=8.83×10^{-14}) (**Figure 3A**).

We then developed ML models to predict binary C/T resistance using the same dataset,

achieving an average area under receiver operator curve (AUROC) of 0.65, and log-loss of

0.26 (**Supplementary Figure 5**). Across all model iterations, 369 unitigs were selected. To

refine the list of candidates, we intersected GWAS-significant unitigs with those selected by

the models, applying thresholds of a minimum allele frequency ≥0.1 and presence in at least 5

model iterations (**Figure 3B**, **Supplementary Table 4**). This filtering yielded five key genes:

ftsI and *ampR* were selected in all models, while PA4311, PA3329, and *ampC* appeared in

8/10, 6/10, and 6/10 models, respectively.

Binding affinity assessment for significant variants

ftsI emerged as a key determinant of C/T resistance in analysis of known resistance mechanisms, as well as GWAS/ML analysis. These findings and the fact that PBP3 is a target of ceftolozane prompted investigation of mutation impacts on *in silico* binding affinity[26]. We identified four non-synonymous mutations in GWAS-significant unitigs mapped to *ftsI*: R504C (n=38), F507I (n=1), T514A (n=1), and R504H (n=1). Among these, only R504C was significantly associated with resistant isolates (21/114 [18.4%], P=1.57×10^{-26}) while the others were exclusively found in susceptible isolates. Molecular docking analysis revealed significantly higher binding affinity between ceftolozane and wild type PBP3 compared to mutant PBP3 (R504C) (-3.520 vs -2.814 kcal/mol, P=0.016) (**Supplementary Figure 6**), with loss of contact at A244 and single hydrogen bonds at Q265 and T267 (cf. double bonds in wild type PBP3) (**Figure 4**). These changes potentially explain reduced drug binding and consequent resistance.

We extended our docking analysis to the novel proteins encoded by PA3329 and PA4311. The PA3329-encoded protein showed no meaningful binding affinity to ceftolozane (mean: 924.393 kcal/mol, SD: 288.148). The PA4311-encoded protein demonstrated binding affinity (-1.493 kcal/mol, 1.459) with potential binding sites at D116, Q271, R292 and G294 (**Supplementary Figure 7**).

Discussion

This comprehensive genomic analysis of 1,682 *P. aeruginosa* isolates has revealed multiple mechanisms contributing to C/T resistance, including previously known resistance determinants (*ftsI*, *ampC*, and *ampR*) and novel candidates (PA3329 and PA4311). *ftsI* emerged as a key contributor to C/T resistance across multiple analyses. These findings were

underscored by several methodological strengths. Our study leveraged a large, geographically

diverse dataset incorporating both novel and public genome sequences to provide robust

statistical power and broad representativeness. Additionally, our multi-modal approach, which

combines GWAS, ML, and molecular docking, enabled cross-validation of findings through

complementary methodologies.

Ceftolozane is a potent inhibitor of PBP3 encoded by *ftsI*[26]. Our study noted that mutations in

ftsI were highly associated with C/T resistance, being present in 24/114 resistant vs 22/1,328

susceptible isolates (P=2.70×10^{-28}), specifically the R504C mutation. This was then further

confirmed in our GWAS and ML analyses, which both identified *ftsI* as the top-ranking

contributor to C/T resistance. Our docking analysis then demonstrated that mutant *ftsI*

(R504C) significantly reduced ceftolozane binding affinity, providing a mechanistic explanation

for resistance. The role of PBP3 in β-lactam resistance has been increasingly recognised, not

only in *P. aeruginosa*[7], but also across various Enterobacterales[27,28]. Although the R504C

mutation was previously documented to emerge following C/T exposure[11], its importance in

C/T resistance has been potentially underappreciated, as research has primarily focused on

β-lactamases[8,29]. Furthermore, its co-occurrence with other mutations may have obscured its

individual contribution to resistance[7,8,11], highlighting the value of GWAS approach in

identifying specific resistance determinants.

Our analysis of genes previously associated with C/T resistance[5] showed that they likely have

differing contributions when studied in a diverse international dataset. We applied a multi-

modal approach to assess the contribution of resistance genes by applying both a traditional

genomic analysis looking at genes associated with C/T resistance in the literature, and GWAS

and ML approaches to allow us to identify key resistance genes *a priori.* Mutations in *ampC*

and its regulator genes were found in all resistant isolates. Amongst these some were

confirmed to have strong contributory effects (e.g. *ampC* and *ampR*) but others contributed

less (e.g. GWAS suggested limited contributions from *ampD*). In some C/T resistance genes

we detected very few mutations (e.g. *galU* in 2.6% of resistant isolates) and in some we did

not detect mutations at all (*dacB).* These findings highlight the complex nature of C/T

resistance mechanisms in *P. aeruginosa*. To try to account for some of these interactions, we

assessed the impact of multiple mutations and noted step-wise increases in MIC with the

number of mutations, both when considering all non-synonymous mutations and when

considering high-impact mutations alone.

The contribution of horizontally acquired β-lactamase genes to C/T resistance has been well

described[8,9], specifically key carbapenemases including bla_{VIM}, bla_{IMP}, bla_{NDM}, and bla_{KPC}.

While we noted these carbapenemases in 12.2% isolates in our study, we also showed that

specific bla_{OXA} and bla_{VEB} genes may play an important role. Four bla_{OXA} genes (bla_{OXA-14},

$bla_{OXA-141}$, $bla_{OXA-210}$, and $bla_{OXA-796}$) and all bla_{VEB} genes were found exclusively in resistant

isolates. These findings confirm prior studies that identified bla_{OXA} gene acquisition as a

common cause of C/T resistance (particularly bla_{OXA-14})[8], as well as noting an association

between bla_{VEB} gene acquisition and C/T resistance[30].

Our study had several limitations. Firstly, the retrospective nature of the analysis and potential

sampling bias in the dataset may affect generalizability. Secondly, functional validation of

novel genetic determinants PA3329 and PA4311 is crucial to understand their role in

resistance. While PA3329 has not been previously associated with C/T resistance, mutations

in PA4311 have been observed following seven days of C/T exposure[6]. However, the

emergence of mutations in multiple genes complicates the identification of key resistance

drivers. Although tools like AlphaFold offer advances in structure and binding prediction,

computational inference of protein function, particularly for hypothetical proteins, remains

limited. Lastly, while docking analysis suggests reduced ceftolozane binding to mutant PBP3,

in vitro studies are required to confirm these findings.

In conclusion, our study rigorously determined the genetic underpinnings of C/T resistance

and revealed complex pathways leading to C/T resistance. *ampC* and its regulators were

confirmed to play an important role but we demonstrated that *ftsI* may be a more significant

contributor than previously recognized. We also identified two novel determinants whose

functions remains to be determined. The hypotheses generated by our study present an

opportunity for validation through both computational and experimental approaches to

understand the functional mechanisms of these newly identified determinants.

Author contributions

HA.N, N.M. and A.Y.P. conceived the study. J.A.W. designed and supervised sampling and

collection of bacterial isolates. J.A.W., L.V.B., G.Z.B, R.T., N.Q.D., and M.H.P. collected the

bacterial isolates, performed bacterial characterization, conducted genome sequencing and

broth microdilution. HA.N. preprocessed WGS data. HA.N., J.S., D.L.D., and N.M.

conceptualized machine learning analyses. HA.N. conducted GWAS, developed machine

learning models. HA.N. and N.M. analyzed all results. HA.N. and N.M. wrote the manuscript

with comments and feedback of all of the co-authors. All authors read and approved the

manuscript.

Funding

This work was supported by the National Health and Medical Research Council of Australia (Emerging Leader 1 Fellowship APP1176324 to N.M. and Practitioner Fellowship APP1117940 to A.Y.P) and the Australian Medical Research Future Fund (FSPGN000048). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Competing interests

N.M. has received research support from GlaxoSmithKline, unrelated to the current study. A.Y.P. has received research funding from MSD through an investigator-initiated research project. All other authors declare no conflict of interest.

Acknowledgement

This work was supported by Monash eResearch Centre, including the M3 service. This work was also supported by use of the Nectar Research Cloud, a collaborative Australian research platform supported by the NCRIS-funded Australian Research Data Commons (ARDC).

References

1.   Naghavi M, Vollset SE, Ikuta KS, et al. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. *The Lancet*. 2024;404(10459):1199-1226. doi:10.1016/S0140-6736(24)01867-1

2.   Horcajada JP, Montero M, Oliver A, et al. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant *Pseudomonas aeruginosa* Infections. *Clinical Microbiology Reviews*. 2019;32(4):10.1128/cmr.00031-19. doi:doi:10.1128/cmr.00031-19

3.   Macesic N, Uhlemann A-C, Peleg AY. Multidrug-resistant Gram-negative bacterial infections. *The Lancet*. 2025;405(10474):257-272. doi:10.1016/S0140-6736(24)02081-6

4.   Kostoulias X, Chang CC, Wisniewski J, et al. Antimicrobial susceptibility of ceftolozane-
tazobactam against multidrug-resistant *Pseudomonas aeruginosa* isolates from Melbourne, Australia.
Pathology. 2023;55(5):663-668. doi:10.1016/j.pathol.2023.03.009
5.   Cortes-Lara S, Barrio-Tofiño Ed, López-Causapé C, et al. Predicting *Pseudomonas aeruginosa*
susceptibility phenotypes from whole genome sequence resistome analysis. *Clinical Microbiology and*
Infection. 2021;27(11):1631-1637. doi:10.1016/j.cmi.2021.05.011
6.   Cabot G, Bruchmann S, Mulet X, et al. *Pseudomonas aeruginosa* Ceftolozane-Tazobactam
Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural
Modification of AmpC. *Antimicrobial Agents and Chemotherapy*. 2014;58(6):3091-3099.
doi:doi:10.1128/aac.02462-13
7.   Tamma PD, Beisken S, Bergman Y, et al. Modifiable Risk Factors for the Emergence of
Ceftolozane-tazobactam Resistance. *Clinical Infectious Diseases*. 2020;73(11):e4599-e4606.
doi:10.1093/cid/ciaa1306
8.   Fraile-Ribot PA, Cabot G, Mulet X, et al. Mechanisms leading to in vivo ceftolozane/tazobactam
resistance development during the treatment of infections caused by MDR *Pseudomonas aeruginosa*.
Journal of Antimicrobial Chemotherapy. 2017;73(3):658-663. doi:10.1093/jac/dkx424
9.   Karlowsky JA, Lob SH, Estabrook MA, et al. Susceptibility profile and β-lactamase content of
global *Pseudomonas aeruginosa* isolates resistant to ceftolozane/tazobactam and/or
imipenem/relebactam—SMART 2016–21. *JAC-Antimicrobial Resistance*.
2023;5(3)doi:10.1093/jacamr/dlad080
10.   del Barrio-Tofiño E, Zamorano L, Cortes-Lara S, et al. Spanish nationwide survey on
Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology. *Journal of*
Antimicrobial Chemotherapy. 2019;74(7):1825-1835. doi:10.1093/jac/dkz147
11.   Rubio AM, Kline EG, Jones CE, et al. *In Vitro* Susceptibility of Multidrug-Resistant *Pseudomonas*
aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. *Antimicrobial*
Agents and Chemotherapy. 2021;65(6):10.1128/aac.00084-21. doi:doi:10.1128/aac.00084-21
12.   Barrio-Tofiño Ed, López-Causapé C, Cabot G, et al. Genomics and Susceptibility Profiles of
Extensively Drug-Resistant *Pseudomonas aeruginosa* Isolates from Spain. *Antimicrobial Agents and*
Chemotherapy. 2017;61(11):10.1128/aac.01589-17. doi:doi:10.1128/aac.01589-17
13.   Teo Jocelyn Q-M, Lim Jie C, Tang Cheng Y, et al. Ceftolozane/Tazobactam Resistance and
Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa. *mSphere*.
2021;6(1):10.1128/msphere.01026-20. doi:10.1128/msphere.01026-20
14.   Stanton RA, Campbell D, McAllister GA, et al. Whole-Genome Sequencing Reveals Diversity of
Carbapenem-Resistant *Pseudomonas aeruginosa* Collected through CDC's Emerging Infections
Program, United States, 2016-2018. *Antimicrobial Agents and Chemotherapy*. 2022;66(9):e00496-22.
doi:doi:10.1128/aac.00496-22
15.   Sastre-Femenia MÀ, Fernández-Muñoz A, Gomis-Font MA, et al. *Pseudomonas aeruginosa*
antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-
year time lapse analysis. *The Lancet Regional Health – Europe*.
2023;34doi:10.1016/j.lanepe.2023.100736
16.   European Committee on Antimicrobial Susceptibility Testing (EUCAST). *Breakpoint tables for*
interpretation of MICs and zone diameters. Version 15.0, valid from 2025-01-01. 2023.
17.   Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: Resolving bacterial genome assemblies from
short and long sequencing reads. *PLOS Computational Biology*. 2017;13(6):e1005595.
doi:10.1371/journal.pcbi.1005595

18.   Feldgarden M, Brover V, Gonzalez-Escalona N, et al. AMRFinderPlus and the Reference Gene
Catalog facilitate examination of the genomic links among antimicrobial resistance, stress response,
and virulence. *Scientific Reports*. 2021/06/16 2021;11(1):12728. doi:10.1038/s41598-021-91456-0
19.   Lees JA, Galardini M, Bentley SD, Weiser JN, Corander J. pyseer: a comprehensive tool for
microbial pangenome-wide association studies. *Bioinformatics*. 2018;34(24):4310-4312.
doi:10.1093/bioinformatics/bty539
20.   Mirdita M, Schütze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold: making
protein folding accessible to all. *Nature Methods*. 2022/06/01 2022;19(6):679-682.
doi:10.1038/s41592-022-01488-1
21.   Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: New Docking Methods,
Expanded Force Field, and Python Bindings. *Journal of Chemical Information and Modeling*.
2021/08/23 2021;61(8):3891-3898. doi:10.1021/acs.jcim.1c00203
22.   Schrödinger LLC. The PyMOL Molecular Graphics System, Version 1.8. 2015.
23.   Hernández-García M, García-Castillo M, García-Fernández S, et al. Distinct epidemiology and
resistance mechanisms affecting ceftolozane/tazobactam in *Pseudomonas aeruginosa* isolates
recovered from ICU patients in Spain and Portugal depicted by WGS. *Journal of Antimicrobial
Chemotherapy*. 2020;76(2):370-379. doi:10.1093/jac/dkaa430
24.   Simner PJ, Beisken S, Bergman Y, Posch AE, Cosgrove SE, Tamma PD. Cefiderocol Activity Against
Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance. *Open Forum
Infectious Diseases*. 2021;8(7):ofab311. doi:10.1093/ofid/ofab311
25.   Díaz-Cañestro M, Periañez L, Mulet X, et al. Ceftolozane/tazobactam for the treatment of
multidrug resistant *Pseudomonas aeruginosa*: experience from the Balearic Islands. *European Journal
of Clinical Microbiology & Infectious Diseases*. 2018/11/01 2018;37(11):2191-2200.
doi:10.1007/s10096-018-3361-0
26.   Moyá B, Zamorano L, Juan C, Ge Y, Oliver A. Affinity of the New Cephalosporin CXA-101 to
Penicillin-Binding Proteins of *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy*.
2010;54(9):3933-3937. doi:doi:10.1128/aac.00296-10
27.   Le Terrier C, Nordmann P, Buchs C, Poirel L. Effect of modification of penicillin-binding protein 3
on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam,
aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing
broad-spectrum β-lactamases. *Antimicrobial Agents and Chemotherapy*. 2024;68(4):e01548-23.
doi:10.1128/aac.01548-23
28.   Mushtaq S, Vickers A, Woodford N, Livermore DM. Activity of aztreonam/avibactam and
ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem
resistance. *International Journal of Antimicrobial Agents*. 2024/03/01 2024;63(3):107081.
doi:https://doi.org/10.1016/j.ijantimicag.2023.107081
29.   Gomis-Font MA, Cabot G, López-Argüello S, et al. Comparative analysis of in vitro dynamics and
mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in
Pseudomonas aeruginosa XDR high-risk clones. *Journal of Antimicrobial Chemotherapy*.
2022;77(4):957-968. doi:10.1093/jac/dkab496
30.   Livermore DM, Mushtaq S, Ge Y, Warner M. Activity of cephalosporin CXA-101 (FR264205)
against *Pseudomonas aeruginosa* and *Burkholderia cepacia* group strains and isolates. *International
Journal of Antimicrobial Agents*. 2009/11/01 2009;34(5):402-406.
doi:https://doi.org/10.1016/j.ijantimicag.2009.03.021
438

Figure 1. Overall workflow of the study. This figure was created with BioRender.com.

Figure 2. (A) Impact of mutations in chromosomal genes known to affect C/T

susceptibility. P-values were calculated using the Chi-square test. **(B) Pathways to C/T**

resistance at gene level. Each unique combination of mutations in genes associated with

C/T resistance is shown as a unique pathway. **(C) Distinct pathways to C/T resistance,**

collapsed to resistance mechanisms. Here, the genes associated with C/T resistance are

collapsed into mechanistic groupings. Each unique combination of mutations in mechanistic

groupings is shown as a unique pathway. **(D, E) MIC values with respect to the cumulation**

of mutations (all non-synonymous mutations [D] vs high-impact mutations only [E]) in

chromosomal genes known for C/T resistance. Dots and vertical bars indicate mean and

standard deviation (SD) of MIC values, respectively.

Figure 3. (A) Genes selected by GWAS study, with the maximum P-value (y-axis) and

the average minimum allele frequency (MAF) (x-axis). (B) Genes (y-axis) selected by

both GWAS and ML approach, and their occurrence in ML models (x-axis).

459 A.   B.

460 **Figure 4. 3D structure visualization of the interaction of ceftolozane (pink) to R504C**

461 **mutant PBP3 (Panel A) and wild type PBP3 (Panel B).** Dashed yellow lines indicate

462 hydrogen bonds. The R504C mutant (**Panel A**) shows loss of contact at A244 and single

463 hydrogen bonds at positions Q265 and T267 (cf. double bonds in wild type PBP3 – **Panel B**).